ClinicalTrials.gg
TerminatedNCT04745806Updated Nov 15, 2024

Post Marketing Trial for Evaluating the Effectiveness of ActiGraft in Treating Lower Extremity Hard To Heal Wounds

An interventional study of ActiGraft in Wounds, sponsored by RedDress Ltd.. Terminated at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-15.

Sponsored by RedDress Ltd. · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
low enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study is a prospective, single arm, post- marketing study. The subjects enrolled to the study will receive weekly applications of ActiGraft until complete healing or until investigator's decision that patient can no longer benefit from the study treatment.

02

Conditions studied

  • Wounds

Keywords

  • Chronic
  • Ulcer
  • Lower extremity
  • DFU
  • VLU
03

In context

Wounds and Injuries

2,221 studies on the registry are indexed under Wounds and Injuries; 442 are open to participants now.

This study's enrollment of 6 is below the median of 70 across 1,426 interventional studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

RedDress Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is ≥18 years of age
  2. Patient with a chronic lower extremity ulcer (i.e DFU, VLU, ...)
  3. Ulcer duration >30 days.
  4. Ulcer size decreased in less than 30% in the 14 days prior to enrollment, while treated with standard of care (or advanced treatment)
  5. Subject must be willing to comply with the protocol including having blood drawn to create the ActiGraft
  6. Subject can read and understand the form

Exclusion criteria

Exclusion Criteria:

  1. Presence of active underlying osteomyelitis.
  2. Known in the reference wound bed or margins of the wound
  3. Cannot withdraw blood in the required amount technically.
  4. Subject is receiving (i.e., within the past 30 days) systemic (more than 10mg per day)
  5. Subject has been treated with wound dressings that include growth factors, engineered tissues or skin substitutes (within the past 30 days).
  6. Subject has been treated with hyperbaric oxygen, wound VAC or Ozone gas(O3) within the past 5 days or is scheduled to receive during the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    ActiGraft

    Whole blood clot (WBC) gel

    Device: ActiGraft

Interventions

  • DeviceActiGraft

    Whole blood clot (WBC) gel

06

What researchers measure

Primary outcomes

  1. Percent of Reduction in Wound Size Over 12 Weeks

    The change in wound area (decrease or increase) with respect to the area at baseline, expressed as a percentage.

    Time frame: 4, 8, and 12 weeks

Secondary outcomes

  1. Number of Participants Achieving a Complete Wound Closure at 12 Weeks

    Skin re-epithelialization without drainage or dressing requirements.

    Time frame: 12 weeks

  2. Number of Participants Achieving a Complete re-epithelialization at 18 and 24 Weeks

    Skin re-epithelialization without drainage or dressing requirements.

    Time frame: 18 and 24 weeks

  3. Percent of Reduction in Wound Size Over 18 and 24 Weeks.

    The change in wound area (decrease or increase) with respect to the area at baseline, expressed as a percentage for wound treated beyond 12 weeks, per the investigator's decision

    Time frame: 18 and 24 weeks

  4. The change in wound pain by 12 weeks

    Pain assessment would be done by using the Numeric Rating Scale (NRS). Subject chooses a number on a 1 to 10 scale that best describes his ulcer pain, while 0 represents "No Pain" and 10- " Worst Pain Imaginable "test, a scale between .

    Time frame: 12 weeks

07

Study locations

1 site
  • Emek Medical Center
    Afula, Israel
08

References and documents

Individual participant data

Plan to share: Yes — The results will be part of several scientific publications.

Supporting information: Study protocol

Time frame: Upon publication.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Jan 2023, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2021
First posted
Feb 9, 2021
StartActual
Mar 1, 2021
Primary completionActual
Jan 1, 2023
CompletionActual
Jan 1, 2023
Last update
Nov 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04745806
Lead sponsor
RedDress Ltd.
Responsible party
Sponsor
First posted
Feb 9, 2021
Start date
Mar 1, 2021
Primary completion
Jan 1, 2023
Completion
Jan 1, 2023
Last update
Nov 15, 2024

Study contacts

Sharon Sirota
study director · RedDress Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion